Washington Trust Advisors’s Axsome Therapeutics AXSM Stock Holding History

Washington Trust Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.8K	Sell	175 -75	-30%	-$16.3K	﹤0.01%	392
2026 Q1	$42.3K	Hold	250	–	–	﹤0.01%	370
2025 Q4	$45.7K	Hold	250	–	–	﹤0.01%	362
2025 Q3	$30.4K	Hold	250	–	–	﹤0.01%	402
2025 Q2	$26.1K	Hold	250	–	–	﹤0.01%	376
2025 Q1	$29.2K	Sell	250 -80	-24%	-$9.11K	﹤0.01%	366
2024 Q4	$27.9K	Hold	330	–	–	﹤0.01%	379
2024 Q3	$29.7K	Hold	330	–	–	﹤0.01%	384
2024 Q2	$26.6K	Hold	330	–	–	﹤0.01%	379
2024 Q1	$26.3K	Hold	330	–	–	﹤0.01%	376
2023 Q4	$26.3K	Buy	+330	New	+$22.1K	﹤0.01%	369

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Washington Trust Advisors's AXSM Position: Q2 2026 in Review

Washington Trust Advisors reduced its Axsome Therapeutics (AXSM) stake by 30% in Q2 2026, selling an estimated $16.3K and leaving 175 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #392.

Washington Trust Advisors first reported a position in AXSM in Q4 2023 and has held it in 11 quarters since. The position peaked at $45.7K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Washington Trust Advisors held 175 shares of Axsome Therapeutics worth $42.8K as of Q2 2026.
Washington Trust Advisors sold 75 Axsome Therapeutics shares in Q2 2026, an estimated $16.3K.
Axsome Therapeutics made up ﹤0.01% of Washington Trust Advisors's portfolio in Q2 2026, its #392 holding.
Washington Trust Advisors first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 11 quarters since.
Washington Trust Advisors's Axsome Therapeutics position peaked at $45.7K in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Washington Trust Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.